Global RNAi for Therapeutic Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Description

The RNAi for Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global RNAi for Therapeutic size is estimated to be USD 536.5 million in 2026 from USD 134.8 million in 2020, with a change XX% between 2020 and 2021. The global RNAi for Therapeutic market size is expected to grow at a CAGR of 41.2% for the next five years.

Market segmentation
RNAi for Therapeutic market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    siRNA
    miRNA
    shRNA

Market segment by Application, can be divided into
    Cancer
    Cardiovascular
    HBV
    Others

Market segment by players, this report covers
    Alnylam Pharmaceuticals
    Arbutus Biopharma (Tekmira)
    Arrowhead
    Dicerna Pharmaceuticals
    Mirna Therapeutics
    Quark Pharmaceuticals
    RXi Pharmaceuticals
    Silence Therapeutics
    Benitec Biopharma
    miRagen Therapeutics
    Sylentis
    Gradalis
    Sirnaomics
    Silenseed

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2019 to 2021.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and RNAi for Therapeutic market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe RNAi for Therapeutic research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of RNAi for Therapeutic
    1.2 Classification of RNAi for Therapeutic by Type
        1.2.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global RNAi for Therapeutic Revenue Market Share by Type in 2020
        1.2.3 siRNA
        1.2.4 miRNA
        1.2.5 shRNA
    1.3 Global RNAi for Therapeutic Market by Application
        1.3.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Cancer
        1.3.3 Cardiovascular
        1.3.4 HBV
        1.3.5 Others
    1.4 Global RNAi for Therapeutic Market Size & Forecast
    1.5 Global RNAi for Therapeutic Market Size and Forecast by Region
        1.5.1 Global RNAi for Therapeutic Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global RNAi for Therapeutic Market Size by Region, (2016-2021)
        1.5.3 North America RNAi for Therapeutic Market Size and Prospect (2016-2026)
        1.5.4 Europe RNAi for Therapeutic Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2016-2026)
        1.5.6 South America RNAi for Therapeutic Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 RNAi for Therapeutic Market Drivers
        1.6.2 RNAi for Therapeutic Market Restraints
        1.6.3 RNAi for Therapeutic Trends Analysis

2 Company Profiles
    2.1 Alnylam Pharmaceuticals
        2.1.1 Alnylam Pharmaceuticals Details
        2.1.2 Alnylam Pharmaceuticals Major Business
        2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
    2.2 Arbutus Biopharma (Tekmira)
        2.2.1 Arbutus Biopharma (Tekmira) Details
        2.2.2 Arbutus Biopharma (Tekmira) Major Business
        2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
        2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
    2.3 Arrowhead
        2.3.1 Arrowhead Details
        2.3.2 Arrowhead Major Business
        2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
        2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Arrowhead Recent Developments and Future Plans
    2.4 Dicerna Pharmaceuticals
        2.4.1 Dicerna Pharmaceuticals Details
        2.4.2 Dicerna Pharmaceuticals Major Business
        2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
    2.5 Mirna Therapeutics
        2.5.1 Mirna Therapeutics Details
        2.5.2 Mirna Therapeutics Major Business
        2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
        2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Mirna Therapeutics Recent Developments and Future Plans
    2.6 Quark Pharmaceuticals
        2.6.1 Quark Pharmaceuticals Details
        2.6.2 Quark Pharmaceuticals Major Business
        2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
    2.7 RXi Pharmaceuticals
        2.7.1 RXi Pharmaceuticals Details
        2.7.2 RXi Pharmaceuticals Major Business
        2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
    2.8 Silence Therapeutics
        2.8.1 Silence Therapeutics Details
        2.8.2 Silence Therapeutics Major Business
        2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
        2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Silence Therapeutics Recent Developments and Future Plans
    2.9 Benitec Biopharma
        2.9.1 Benitec Biopharma Details
        2.9.2 Benitec Biopharma Major Business
        2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
        2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Benitec Biopharma Recent Developments and Future Plans
    2.10 miRagen Therapeutics
        2.10.1 miRagen Therapeutics Details
        2.10.2 miRagen Therapeutics Major Business
        2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
        2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 miRagen Therapeutics Recent Developments and Future Plans
    2.11 Sylentis
        2.11.1 Sylentis Details
        2.11.2 Sylentis Major Business
        2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
        2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Sylentis Recent Developments and Future Plans
    2.12 Gradalis
        2.12.1 Gradalis Details
        2.12.2 Gradalis Major Business
        2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
        2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Gradalis Recent Developments and Future Plans
    2.13 Sirnaomics
        2.13.1 Sirnaomics Details
        2.13.2 Sirnaomics Major Business
        2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
        2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 Sirnaomics Recent Developments and Future Plans
    2.14 Silenseed
        2.14.1 Silenseed Details
        2.14.2 Silenseed Major Business
        2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
        2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 Silenseed Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global RNAi for Therapeutic Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 RNAi for Therapeutic Players Market Share
        3.2.2 Top 10 RNAi for Therapeutic Players Market Share
        3.2.3 Market Competition Trend
    3.3 RNAi for Therapeutic Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global RNAi for Therapeutic Revenue and Market Share by Type (2016-2021)
    4.2 Global RNAi for Therapeutic Market Forecast by Type (2021-2026)

5 Market Size Segment by Application
    5.1 Global RNAi for Therapeutic Revenue Market Share by Application (2016-2021)
    5.2 RNAi for Therapeutic Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application
    6.1 North America RNAi for Therapeutic Revenue by Type (2016-2026)
    6.2 North America RNAi for Therapeutic Revenue by Application (2016-2026)
    6.3 North America RNAi for Therapeutic Market Size by Country
        6.3.1 North America RNAi for Therapeutic Revenue by Country (2016-2026)
        6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2016-2026)
        6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2016-2026)
        6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application
    7.1 Europe RNAi for Therapeutic Revenue by Type (2016-2026)
    7.2 Europe RNAi for Therapeutic Revenue by Application (2016-2026)
    7.3 Europe RNAi for Therapeutic Market Size by Country
        7.3.1 Europe RNAi for Therapeutic Revenue by Country (2016-2026)
        7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2016-2026)
        7.3.3 France RNAi for Therapeutic Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2016-2026)
        7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2016-2026)
        7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific RNAi for Therapeutic Revenue by Type (2016-2026)
    8.2 Asia-Pacific RNAi for Therapeutic Revenue by Application (2016-2026)
    8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
        8.3.1 Asia-Pacific RNAi for Therapeutic Revenue by Region (2016-2026)
        8.3.2 China RNAi for Therapeutic Market Size and Forecast (2016-2026)
        8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2016-2026)
        8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2016-2026)
        8.3.5 India RNAi for Therapeutic Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2016-2026)
        8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application
    9.1 South America RNAi for Therapeutic Revenue by Type (2016-2026)
    9.2 South America RNAi for Therapeutic Revenue by Application (2016-2026)
    9.3 South America RNAi for Therapeutic Market Size by Country
        9.3.1 South America RNAi for Therapeutic Revenue by Country (2016-2026)
        9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2016-2026)
        9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa RNAi for Therapeutic Revenue by Type (2016-2026)
    10.2 Middle East & Africa RNAi for Therapeutic Revenue by Application (2016-2026)
    10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
        10.3.1 Middle East & Africa RNAi for Therapeutic Revenue by Country (2016-2026)
        10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2016-2026)
        10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global RNAi for Therapeutic Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global RNAi for Therapeutic Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market RNAi for Therapeutic Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global RNAi for Therapeutic Revenue (USD Million) by Region (2016-2021)
    Table 5. Global RNAi for Therapeutic Revenue Market Share by Region (2021-2026)
    Table 6. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 7. Alnylam Pharmaceuticals Major Business
    Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 9. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. Arbutus Biopharma (Tekmira) Corporate Information, Head Office, and Major Competitors
    Table 11. Arbutus Biopharma (Tekmira) Major Business
    Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
    Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. Arrowhead Corporate Information, Head Office, and Major Competitors
    Table 15. Arrowhead Major Business
    Table 16. Arrowhead RNAi for Therapeutic Product and Solutions
    Table 17. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. Dicerna Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 19. Dicerna Pharmaceuticals Major Business
    Table 20. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 21. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Mirna Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 23. Mirna Therapeutics Major Business
    Table 24. Mirna Therapeutics RNAi for Therapeutic Product and Solutions
    Table 25. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. Quark Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 27. Quark Pharmaceuticals Major Business
    Table 28. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 29. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. RXi Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 31. RXi Pharmaceuticals Major Business
    Table 32. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
    Table 33. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. Silence Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 35. Silence Therapeutics Major Business
    Table 36. Silence Therapeutics RNAi for Therapeutic Product and Solutions
    Table 37. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Benitec Biopharma Corporate Information, Head Office, and Major Competitors
    Table 39. Benitec Biopharma Major Business
    Table 40. Benitec Biopharma RNAi for Therapeutic Product and Solutions
    Table 41. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. miRagen Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 43. miRagen Therapeutics Major Business
    Table 44. miRagen Therapeutics RNAi for Therapeutic Product and Solutions
    Table 45. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Sylentis Corporate Information, Head Office, and Major Competitors
    Table 47. Sylentis Major Business
    Table 48. Sylentis RNAi for Therapeutic Product and Solutions
    Table 49. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 50. Gradalis Corporate Information, Head Office, and Major Competitors
    Table 51. Gradalis Major Business
    Table 52. Gradalis RNAi for Therapeutic Product and Solutions
    Table 53. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 54. Sirnaomics Corporate Information, Head Office, and Major Competitors
    Table 55. Sirnaomics Major Business
    Table 56. Sirnaomics RNAi for Therapeutic Product and Solutions
    Table 57. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 58. Silenseed Corporate Information, Head Office, and Major Competitors
    Table 59. Silenseed Major Business
    Table 60. Silenseed RNAi for Therapeutic Product and Solutions
    Table 61. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 62. Global RNAi for Therapeutic Revenue (USD Million) by Players (2019-2021)
    Table 63. Global RNAi for Therapeutic Revenue Share by Players (2019-2021)
    Table 64. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 65. RNAi for Therapeutic Players Head Office, Products and Services Provided
    Table 66. RNAi for Therapeutic Mergers & Acquisitions in the Past Five Years
    Table 67. RNAi for Therapeutic New Entrants and Expansion Plans
    Table 68. Global RNAi for Therapeutic Revenue (USD Million) by Type (2016-2021)
    Table 69. Global RNAi for Therapeutic Revenue Share by Type (2016-2021)
    Table 70. Global RNAi for Therapeutic Revenue Forecast by Type (2021-2026)
    Table 71. Global RNAi for Therapeutic Revenue by Application (2016-2021)
    Table 72. Global RNAi for Therapeutic Revenue Forecast by Application (2021-2026)
    Table 73. North America RNAi for Therapeutic Revenue by Type (2016-2021) & (USD Million)
    Table 74. North America RNAi for Therapeutic Revenue by Type (2021-2026) & (USD Million)
    Table 75. North America RNAi for Therapeutic Revenue by Application (2016-2021) & (USD Million)
    Table 76. North America RNAi for Therapeutic Revenue by Application (2021-2026) & (USD Million)
    Table 77. North America RNAi for Therapeutic Revenue by Country (2016-2021) & (USD Million)
    Table 78. North America RNAi for Therapeutic Revenue by Country (2021-2026) & (USD Million)
    Table 79. Europe RNAi for Therapeutic Revenue by Type (2016-2021) & (USD Million)
    Table 80. Europe RNAi for Therapeutic Revenue by Type (2021-2026) & (USD Million)
    Table 81. Europe RNAi for Therapeutic Revenue by Application (2016-2021) & (USD Million)
    Table 82. Europe RNAi for Therapeutic Revenue by Application (2021-2026) & (USD Million)
    Table 83. Europe RNAi for Therapeutic Revenue by Country (2016-2021) & (USD Million)
    Table 84. Europe RNAi for Therapeutic Revenue by Country (2021-2026) & (USD Million)
    Table 85. Asia-Pacific RNAi for Therapeutic Revenue by Type (2016-2021) & (USD Million)
    Table 86. Asia-Pacific RNAi for Therapeutic Revenue by Type (2021-2026) & (USD Million)
    Table 87. Asia-Pacific RNAi for Therapeutic Revenue by Application (2016-2021) & (USD Million)
    Table 88. Asia-Pacific RNAi for Therapeutic Revenue by Application (2021-2026) & (USD Million)
    Table 89. Asia-Pacific RNAi for Therapeutic Revenue by Region (2016-2021) & (USD Million)
    Table 90. Asia-Pacific RNAi for Therapeutic Revenue by Region (2021-2026) & (USD Million)
    Table 91. South America RNAi for Therapeutic Revenue by Type (2016-2021) & (USD Million)
    Table 92. South America RNAi for Therapeutic Revenue by Type (2021-2026) & (USD Million)
    Table 93. South America RNAi for Therapeutic Revenue by Application (2016-2021) & (USD Million)
    Table 94. South America RNAi for Therapeutic Revenue by Application (2021-2026) & (USD Million)
    Table 95. South America RNAi for Therapeutic Revenue by Country (2016-2021) & (USD Million)
    Table 96. South America RNAi for Therapeutic Revenue by Country (2021-2026) & (USD Million)
    Table 97. Middle East & Africa RNAi for Therapeutic Revenue by Type (2016-2021) & (USD Million)
    Table 98. Middle East & Africa RNAi for Therapeutic Revenue by Type (2021-2026) & (USD Million)
    Table 99. Middle East & Africa RNAi for Therapeutic Revenue by Application (2016-2021) & (USD Million)
    Table 100. Middle East & Africa RNAi for Therapeutic Revenue by Application (2021-2026) & (USD Million)
    Table 101. Middle East & Africa RNAi for Therapeutic Revenue by Country (2016-2021) & (USD Million)
    Table 102. Middle East & Africa RNAi for Therapeutic Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. RNAi for Therapeutic Picture
    Figure 2. Global RNAi for Therapeutic Revenue Market Share by Type in 2020
    Figure 3. siRNA
    Figure 4. miRNA
    Figure 5. shRNA
    Figure 6. RNAi for Therapeutic Revenue Market Share by Application in 2020
    Figure 7. Cancer Picture
    Figure 8. Cardiovascular Picture
    Figure 9. HBV Picture
    Figure 10. Others Picture
    Figure 11. Global RNAi for Therapeutic Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 12. Global RNAi for Therapeutic Revenue and Forecast (2016-2026) & (USD Million)
    Figure 13. Global RNAi for Therapeutic Revenue Market Share by Region (2016-2026)
    Figure 14. Global RNAi for Therapeutic Revenue Market Share by Region in 2020
    Figure 15. North America RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 16. Europe RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. Asia-Pacific RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. South America RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 19. Middle East and Africa RNAi for Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 20. RNAi for Therapeutic Market Drivers
    Figure 21. RNAi for Therapeutic Market Restraints
    Figure 22. RNAi for Therapeutic Market Trends
    Figure 23. Alnylam Pharmaceuticals Recent Developments and Future Plans
    Figure 24. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
    Figure 25. Arrowhead Recent Developments and Future Plans
    Figure 26. Dicerna Pharmaceuticals Recent Developments and Future Plans
    Figure 27. Mirna Therapeutics Recent Developments and Future Plans
    Figure 28. Quark Pharmaceuticals Recent Developments and Future Plans
    Figure 29. RXi Pharmaceuticals Recent Developments and Future Plans
    Figure 30. Silence Therapeutics Recent Developments and Future Plans
    Figure 31. Benitec Biopharma Recent Developments and Future Plans
    Figure 32. miRagen Therapeutics Recent Developments and Future Plans
    Figure 33. Sylentis Recent Developments and Future Plans
    Figure 34. Gradalis Recent Developments and Future Plans
    Figure 35. Sirnaomics Recent Developments and Future Plans
    Figure 36. Silenseed Recent Developments and Future Plans
    Figure 37. Global RNAi for Therapeutic Revenue Share by Players in 2020
    Figure 38. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 39. Global Top 3 Players RNAi for Therapeutic Revenue Market Share in 2020
    Figure 40. Global Top 10 Players RNAi for Therapeutic Revenue Market Share in 2020
    Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 42. Global RNAi for Therapeutic Revenue Share by Type in 2020
    Figure 43. Global RNAi for Therapeutic Market Share Forecast by Type (2021-2026)
    Figure 44. Global RNAi for Therapeutic Revenue Share by Application in 2020
    Figure 45. Global RNAi for Therapeutic Market Share Forecast by Application (2021-2026)
    Figure 46. North America RNAi for Therapeutic Sales Market Share by Type (2016-2026)
    Figure 47. North America RNAi for Therapeutic Sales Market Share by Application (2016-2026)
    Figure 48. North America RNAi for Therapeutic Revenue Market Share by Country (2016-2026)
    Figure 49. United States RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 50. Canada RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 51. Mexico RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 52. Europe RNAi for Therapeutic Sales Market Share by Type (2016-2026)
    Figure 53. Europe RNAi for Therapeutic Sales Market Share by Application (2016-2026)
    Figure 54. Europe RNAi for Therapeutic Revenue Market Share by Country (2016-2026)
    Figure 55. Germany RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 56. France RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 57. United Kingdom RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 58. Russia RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 59. Italy RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 60. Asia-Pacific RNAi for Therapeutic Sales Market Share by Type (2016-2026)
    Figure 61. Asia-Pacific RNAi for Therapeutic Sales Market Share by Application (2016-2026)
    Figure 62. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Region (2016-2026)
    Figure 63. China RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 64. Japan RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 65. South Korea RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 66. India RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 67. Southeast Asia RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 68. Australia RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 69. South America RNAi for Therapeutic Sales Market Share by Type (2016-2026)
    Figure 70. South America RNAi for Therapeutic Sales Market Share by Application (2016-2026)
    Figure 71. South America RNAi for Therapeutic Revenue Market Share by Country (2016-2026)
    Figure 72. Brazil RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 73. Argentina RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 74. Middle East and Africa RNAi for Therapeutic Sales Market Share by Type (2016-2026)
    Figure 75. Middle East and Africa RNAi for Therapeutic Sales Market Share by Application (2016-2026)
    Figure 76. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Country (2016-2026)
    Figure 77. Turkey RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 78. Saudi Arabia RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 79. UAE RNAi for Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 80. Methodology
    Figure 81. Research Process and Data Source

Companies Mentioned

Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed